The technology transfer organisation of the universities of Basel, Bern and Zurich helped more than 1,2000 new research collaborations in 2016. The funds resulting from…
Jérémie Meyer10.02.2017
The pharmaceutical company Polyphor has received CHF 2.3 million to advance research work on a particular antibiotic. Polyphor has been very successful in developing medicines…
Jérémie Meyer09.02.2017
BaseLaunch, an accelerator initiative launched and run by the location promotion organisation BaselArea.swiss, is a new partner of the start-up accelerator Kickstart. Life sciences start-ups…
Jérémie Meyer01.02.2017
The Basel-based biopharmaceutical company Cellestia Biotech closed a CHF 8 million seed financing round. The funds will help Cellestia advance its lead cancer treatment CB-103…
Jérémie Meyer30.01.2017
US pharmaceutical company Johnson & Johnson is to acquire the biopharmaceutical company Actelion for USD 30 billion. Actelion’s research and development department will spin out…
Jérémie Meyer26.01.2017
The Basel-based biotechnology company Therachon has raised an additional USD 5 million in its latest financing round. It also appointed Luca Santarelli as its new…
Jérémie Meyer17.01.2017
The US investment firm Versant Ventures has launched a new fund worth USD 400 million with the aim of investing in 20 to 25 biotechnology…
Jérémie Meyer13.01.2017
The Basel-based pharmaceutical company PIQUR Therapeutics is entering into a partnership with the French pharmaceutical group Pierre Fabre to collaborate in the field of dermato-oncology.
Jérémie Meyer11.01.2017
